downloadGenomic Health® is a provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early stage cancer.

The company’s flagship product, the Oncotype DX®, breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the test predicts the likelihood of recurrence in ductal carcinoma in situ (DCIS). With half a million patients tested in more than 90 countries, the Oncotype DX tests have redefined personalised medicine by making genomics a critical part of cancer diagnosis and treatment.


VentanaVentana is committed to our mission — to improve the lives of all patients afflicted with cancer.

Our culture of constant innovation fuels our vision: to empower our customers by providing the highest quality, most innovative cancer diagnostic solutions. We are passionate in our pursuit of diagnostic leadership because when we empower pathology professionals, we improve the outlook for patients.

Ventana Medical Systems, Inc., a member of the Roche Group, is a world leader and innovator of tissue-based diagnostic solutions for patients worldwide.

Passionately pursuing their mission to improve the lives of all patients afflicted with cancer, the people of Ventana discover, develop, and deliver medical diagnostic systems and biopsy based cancer tests that are shaping the future of healthcare. As the leading supplier of cancer diagnostic systems to the pathology market, Ventana manufactures over 200 cancer tests with related instruments right here in southern Arizona for 56 countries, and most importantly, for 4 million people afflicted with cancer yearly around the world. Ventana products provide healthcare professionals with a total solution for all critical steps involved in the analysis of tissue biopsies. This pioneering company also offers premier workflow solutions to improve laboratory efficiency and preserve patient safety.

Linking the most accurate diagnosis with the most targeted and relevant therapeutic is the essence of Personalized Healthcare. Clearly, the value of the Personalized Healthcare approach is rooted in positive outcomes for the patient—saving lives and improving the quality of life. Ventana focuses on accelerating the discovery and development of new cancer tests that allow pathologists to analyze patient biopsies at the molecular level to help determine the best course of therapy for each individual patient. As a member of the Roche Group, drawing on powerful partnerships with world-class scientific institutes, there is no company in the world in a better position to make this approach a reality.